• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines - Nature

Mary Wilson

Well-known member
Published 15 March 2023

DOI https://doi.org/10.1038/s41392-023-01396-6

Qiao Wang, Lujia Sun & Shibo Jiang

In a recent study published in Nature, Yan and colleagues demonstrated that NeoCoV, a potential MERS-CoV ancestor in bats, can use bat ACE2 as its entry receptor and that NeoCoV S pseudotyped virus, which contains a T510F mutation in the receptor-binding domain (RBD), enters cells expressing human ACE2 (hACE2).[SUP]1[/SUP] The findings reveal a potential zoonotic threat that MERS-CoV could, during its evolution, be gaining the ability to use hACE2 as an entry receptor and, thus, could also coinfect ACE2-expressing cells with SARS-CoV-2.

It is generally believed that sarbecoviruses, such as SARS-CoV-2 and SARS-CoV, use angiotensin-converting enzyme 2 (ACE2) as the entry receptor, while merbecoviruses, such as MERS-CoV, HKU4, and HKU25, utilize dipeptidyl peptidase 4 (DPP4) as the entry receptor. Some alveolar cells and small intestinal cells in the human body can express both ACE2 and DPP4, providing an opportunity for coinfection by both SARS-CoV-2 and MERS-CoV.

https://www.nature.com/articles/s41392-023-01396-6#citeas
 
Back
Top Bottom